<prompt> Rituximab is an antibody against?CD20CD 52TNFCD 68  <response>: ANSWER: A CD20 REF: Goodman and Gillman 11th edition page 901, Katzung 12th edition page no 646 Repeat Pharmacology December 2009 See APPENDIX-34 below for FDA APPROVED MONOCLONAL ANTIBODIES Rituximab, sold under the trade names Rituxan and MabThera, is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab is used in the treatment of many lymphomas, leukemias, transplant rejection and some autoimmune disorders APPENDIX - 34 FDA Approved Monoclonal Antibodies Antibody Type Target Indication What its approved to treat Abciximab chimeric Inhibition of glycoprotein IlbIIIa Cardiovascular disease Adalimumab human Inhibition of TNF-alpha signaling Several auto-immune disorders Alemtuzumab humanized CD52 Chronic lymphocytic leukemia Basiliximab chimeric IL-2Rc; receptor CD25 Transplant rejection Bevacizumab humanized Vascular endothelial growth factor VEGF Colorectal cancer, Age-related macular degeneration off-label Cetuximab chimeric Epidermal growth factor receptor Colorectal cancer, Head and neck cancer Certolizumab pegol humanized Inhibition of TNF-alpha signaling Crohns disease Daclizumab humanized IL-2Rcr receptor CD 2 5 Transplant rejection Eculizumab humanized Complement system protein C5 Paroxysmal nocturnal hemoglobinuria Efalizumab humanized CDlla Psoriasis Gemtuzumab humanized CD33 Acute myelogenous leukemia with calicheamicin Ibritumomab tiuxetan murine CD20 Non-Hodgkin lymphoma with yttrium- 90 or indium-111 Infliximab chimeric Inhibition of TNF-alpha signaling Several autoimmune disorders Muromonab-CD3 murine T cell CD3 Receptor Transplant rejection Natalizumab humanized Alpha-4 c4 integrin, Multiple sclerosis and Crohns disease Omalizumab humanized Immunoglobulin E IgE Mainly allergy-related asthma Palivizumab humanized An epitope of the RSV F protein Respiratory Syncytial Virus Panitumumab human Epidermal growth factor receptor Colorectal cancer Ranibizumab humanized Vascular endothelial growth factor A VEGF-A Macular degeneration Rituximab chimeric CD20 Non-Hodgkin lymphoma Tositumomab murine CD20 Non-Hodgkin lymphoma Trastuzumab humanized ErbB2 Breast cancer 